Enzolytics Inc (ENZC)

[falon]

Also from the Regeneron Pharmaceuticals, Inc. (REGN) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Question-and-Answer Session

Chris Schott

Great. And just maybe last question for me. You mentioned COVID antibody. That seems to have a pretty unique profile. Just maybe give us a sense of how quickly that could move forward and how much capacity the organization could build with that?

George Yancopoulos

Well, we've shown before that we can move very quickly, and we have capacity to treat millions of patients. And it's going to be less limited by our technologies and our capabilities than our discussions and negotiations with the FDA. And also, at the time that we're doing our clinical studies, what kind of studies will be required by the FDA, part of that negotiation, and also the prevailing amount of disease, which obviously would allow any studies to go more quickly.

Chris Schott

Great. Well, I think we're just out of time. Really appreciate the comments today, and thanks for joining us.


https://seekingalpha.com/article/4568895-regeneron-pharmaceuticals-inc-regn-41st-annual-j-p-morgan-healthcare-conference-transcript